Prevalence, Pathogenesis, and Persistence of Lassa Fever in West Africa

西非拉沙热的流行情况、发病机制和持续性

• 批准号: 10092912
• 负责人: William Fischer
• 金额: $ 72.78万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-02-07 至 2023-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10092912
• 关键词: 5 year old; Acute; Address; Affect; Africa; Area; Awareness; Blood; Caring; Case Fatality Rates; Case Study; Cause of Death; Cervical; Cessation of life; Clinical; Clinical Research; Communicable Diseases; Conflict (Psychology); Country; County; Coupled; Data; Data Collection; Detection; Diagnosis; Diagnostic; Disease; Disease Outbreaks; Documentation; Ebola; Ebola virus; Enrollment; Epidemic; Epidemiology; Fever; Future; Genital; Genitalia; Goals; Guinea; Health; Health Care Research; Health Personnel; Healthcare; Hemorrhage; Hospitals; Immune; Immune response; Immunologic Markers; Incidence; Individual; Infection; Inflammation; Inflammatory; Lassa Fever; Lassa virus; Lead; Liberia; Life; Liquid substance; Longitudinal cohort; Medical History; Microvascular Permeability; Multiple Organ Failure; Natural History; Pathogenesis; Pathogenicity; Pathway interactions; Patient Care; Patients; Physical Examination; Prevalence; Prevention; Procedures; Public Health; Public Policy; Quality Control; RNA; RNA Viruses; Reporting; Research; Research Infrastructure; Research Methodology; Reverse Transcriptase Polymerase Chain Reaction; Risk; Rural; Sampling; Seminal fluid; Series; Seroprevalences; Severities; Sexual Transmission; Sierra Leone; Signs and Symptoms; Site; Standardization; Survivors; Symptoms; Techniques; Therapeutic; Training; Viral; Viral Antigens; Viral Hemorrhagic Fevers; Viral Load result; Viral Pathogenesis; Virus; Virus Diseases; Virus Replication; Virus Shedding; Western Europe; Work; World Health Organization; ZIKA; acute infection; antibody test; climate change; clinical care; clinical infrastructure; cohort; comorbidity; demographics; design; detection platform; diagnostic platform; emerging pathogen; endothelial dysfunction; experience; immune activation; molecular diagnostics; mortality; multidisciplinary; pathogen; pathogenic virus; prevent; priority pathogen; public health relevance; recruit; research and development; transmission process; vaginal fluid; viral RNA

PROJECT SUMMARY Lassa virus (LASV), the causative agent of Lassa fever, is a persistent global public health threat that has infected and killed more people than all Ebola outbreaks combined. Unlike Ebola and other viral hemorrhagic fevers (VHF), Lassa fever is perennial and endemic in West Africa resulting in approximately 300,000 infections and 5,000 deaths each year, principally in Liberia, Sierra Leone, and Guinea. The World Health Organization (WHO) reports that the incidence of Lassa fever is increasing, perhaps as a consequence of climate change, as is the severity and case fatality rate of the disease. As LASV has been imported into non-endemic countries – with more than 32 cases reported, one third of which were fatal – the significance of enhanced detection and management of Lassa fever extends beyond West Africa. Many of these deaths could be prevented with better diagnostics, supportive clinical care, and therapeutics. Yet despite being a major cause of death in West Africa, Lassa fever remains under-diagnosed, understudied, and largely ignored. For these reasons, in 2016, the WHO released a research and development blueprint call-to-action, which identified LASV as a “top priority emerging pathogen” that is likely to cause a severe outbreak in the near future and urgently needs to be studied. Civil unrest coupled with inadequate healthcare and research infrastructure in West Africa have prevented clinical research on this high-priority pathogen, thereby limiting our understanding of the true burden of Lassa fever, the pathogenic mechanisms, and the infectivity of survivors. The primary goal of this proposal is to leverage clinical infrastructure established during the Ebola epidemic to fill critical gaps in our understanding of Lassa fever. Specifically:  In AIM I we will establish molecular diagnostics at Phebe Hospital in Bong county, Liberia – a hyper-endemic area for Lassa fever to determine the prevalence of acute Lassa fever among admitted febrile patients as well as the seroprevalance of prior LASV exposure.  In AIM II we will probe putative pathogenic mechanisms of acute and convalescent Lassa fever including immune activation, endothelial dysfunction, and persistence of viral antigens in genital compartments.  In AIM III we will characterize the compartmental dynamics of LASV in blood, semen and cervical-vaginal fluid to determine the duration of viral shedding and assess the infectivity of PCR-positive samples. We will conduct this work in the context of close and strong working relationships with healthcare leaders in West Africa and a well-developed infrastructure for clinical research we have established in Liberia where we have recruited, enrolled, and longitudinally followed and sampled over 300 Ebola survivors. Establishment of these cohorts allowed our team to determine the feasibility of our approach and develop, pilot, and refine the procedures needed to sustain high-quality data collection during the study of VHFs. This work also allows us to build and support capacity. Our team in Liberia has been trained in research methodology and is being encouraged to develop their own proposals. We have also established a state-of-the-art molecular diagnostic lab and validated a diagnostic platform for the detection of Ebola RNA in blood, semen, and vaginal fluid at Phebe Hospital and have trained this site in quality control. This experience will be applied to the study of Lassa fever. Collectively, the proposed work will provide a much-needed characterization of Lassa fever epidemiology, pathogenesis, and compartmental viral dynamics and will provide a wellspring of data that will inform public policy and individual care. Furthermore, the re-establishment of a Lassa fever center in one of the hardest hit areas will facilitate on-going research to advance the management and prevention of this deadly infectious disease. While much about Lassa fever remains understudied, it is clear that each year this infection will continue to kill more people than all other hemorrhagic viruses combined. What we propose is a series of studies that are long overdue.

项目摘要 拉沙病毒（LASV）是拉沙热的病原体，是一种持续的全球公共卫生威胁， 感染和死亡的人数比所有埃博拉疫情的总和还要多。与埃博拉病毒和其他病毒不同， 拉沙热是西非的一种常年性地方病， 每年约有30万人感染，5,000人死亡，主要是在利比里亚、塞拉利昂和 几内亚.世界卫生组织（世卫组织）报告说，拉沙热的发病率正在上升， 也许是气候变化的结果，疾病的严重程度和病死率也是如此。 由于LASV已输入非流行国家-报告的病例超过32例， 其中有致命的-加强检测和管理拉沙热的重要性 超越西非其中许多死亡可以通过更好的诊断、支持和治疗来预防。 临床护理和治疗学。然而，尽管拉沙热是西非的主要死因， 仍然没有得到充分的诊断和研究，而且在很大程度上被忽视了。2016年，WHO 发布了一份研究和发展蓝图，号召采取行动，将LASV确定为“首要任务 新出现的病原体”，有可能在不久的将来造成严重的爆发，迫切需要 被研究。西非内乱加上医疗保健和研究基础设施不足 阻止了对这种高优先级病原体的临床研究，从而限制了我们对 拉沙热的真正负担、致病机制和幸存者的传染性。的 该提案的主要目标是利用埃博拉疫情期间建立的临床基础设施 填补了我们对拉沙热认识上的重要空白具体而言： 在AIM I中，我们将在利比里亚邦州的Phebe医院建立分子诊断系统， 在拉沙热高度流行地区，以确定急性拉沙热在 入院发热患者以及既往LASV暴露的血清阳性率。 在AIM II中，我们将探讨急性和恢复期拉沙热的假定致病机制 包括免疫激活、内皮功能障碍和生殖器中病毒抗原的持续存在， 隔间 在AIM III中，我们将描述LASV在血液、精液和 宫颈阴道液，以确定病毒脱落的持续时间，并评估 PCR阳性样本。 我们将在与医疗保健部门建立密切和牢固的工作关系的背景下开展这项工作 西非的领导者和我们在西非建立的完善的临床研究基础设施， 在利比里亚，我们招募、登记、纵向跟踪和采样了300多名埃博拉病毒感染者， 幸存者这些队列的建立使我们的团队能够确定我们方法的可行性 并开发、试行和完善维持高质量数据收集所需的程序， 研究VHF。这项工作还使我们能够建设和支持能力。我们在利比里亚的团队 在研究方法方面接受培训，并鼓励他们提出自己的建议。我们有 还建立了一个最先进的分子诊断实验室，并验证了诊断平台， 在Phebe医院检测血液、精液和阴道液中的埃博拉病毒RNA，并对该网站进行了培训 在质量控制方面。这一经验将应用于拉沙热的研究。总体而言，拟议的 这项工作将提供拉沙热流行病学、发病机制和 分区病毒动力学，并将提供一个数据的源泉，将告知公共政策， 个人护理。此外，在受影响最严重的地区之一重建拉沙热中心， 这些领域将促进正在进行的研究，以促进这种致命的管理和预防。 传染病虽然关于拉沙热的许多研究仍然不足，但很明显， 感染将继续导致更多的人死亡，比所有其他出血性病毒的总和还要多。我们 一系列早就应该进行的研究。